@jco-asco.bsky.socialDoes prior systemic chemotherapy exposure influence subsequent response to ROS1 tyrosine kinase inhibitors (TKIs) in ROS1-rearranged non-small-cell lung cancer? Learn more in this #JCOPO systematic review.
Read the article. https://bit.ly/4zc5BHH
@jco-asco.bsky.social#JCOPO Editor-in-Chief Emeritus Dr James Ford & @ascocancer.bsky.social TAPUR Study Founding PI Dr Richard Schilsky discuss the 10-year anniversary of the Targeted Agent and Profiling Utilization Registry (TAPUR)™ Study & its relationship w/ the journal. Listen to the podcast. https://bit.ly/4yPsiRQ